Exicure (Exicure) Growth Rank : 0 (As of May. 27, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Exicure Growth Rank?

Exicure has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Exicure Growth Rank Related Terms

Thank you for viewing the detailed overview of Exicure's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Exicure (Exicure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

2H0A:Germany 2H0A:Germany

Address

2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614

Website

https://www.exicuretx.com

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Executives

Minhee Eom	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd.	10 percent owner	23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim	director, officer: Chief Executive Officer, CFO	46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller	director, officer: Chief Executive Officer, CFO	2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang	director	C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo	director	2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul	director	2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn	director	2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc.	10 percent owner	3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077